Microbiome Shift in Peri-mucositis by Anti-inflammatory Drugs
NCT ID: NCT03090009
Last Updated: 2017-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
100 participants
INTERVENTIONAL
2017-04-30
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The inflammatory burden around diseased implants creates a high-protein environment which is necessary for the survival of pathogenic bacteria. It is logical, therefore, that reducing inflammation by Non Steroidal Anti-Inflammatory Drugs (NSAIDs) may create a shift in the dysbiotic microbiome to a symbiotic microbiome. The aim of the current study is to test the effects of oral NSAIDs on the peri-implant microbiome.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The use of non-steroidal anti-inflammatory drugs (NSAID) to control chronic inflammatory disease has been used extensively in medicine. Its action of blocking cyclooxygenase inflammatory pathway and in-effect blocking the production of Prostaglandin-E2 (PGE2) has led to its use with general pain control as well as its long term use in the treatment of tissue inflammation and pain caused by rheumatoid arthritis or osteoarthritis, tendinitis and bursitis.
Offenbacher et al. as early as in 1981 discovered that patients with periodontitis had significantly higher levels of PGE2 in the sulcular fluid between gingiva and the tooth (GCF) . In a follow up study over a period of 18-36 months, Offenbacher observed that patients who had exhibited periodontal attachment loss had significantly higher levels of PGE2. This led Williams et al. to study the effects of Flurbiprofen, a phenylalkanoic derivative family of of non-steroidal anti-inflammatory drugs, on naturally occurring periodontal disease in an animal model over a period of 12 months. The study demonstrated decreases in alveolar bone loss in flurprofen treated animals at 3, 6 , 9 and 12 months. William et al then followed with a clinical trial where 44 patients who self administered peroral flurbiprofen twice daily for a period of 24 months. The study reported severely depressed bone loss rates over the period of the trial and as early as 6 months after administration of flurbiprofen that continued over the length of the trial. Other studied the drugs effect on other more aggressive forms of the disease with similar results . These results have been duplicated around implants as well. Jeffcoat et al demonstrated that oral intake flurbiprofen helped reduce bone loss around implants in the first year of service. Reddy similarly demonstrated with use of digital subtraction radiography, flurbiprofen taken orally was able to help increase bone density and apposition around implants after just 4 months.
The positive effect of systemic antibiotics and as well topical anti microbials on the pathogenic bacteria in the gingiva sulcus and peri-implant crevice has been well documented and is indisputable. The removal of these bacteria has helped promote tissue health. Similar results have been documented around implants as well. However more recently the reverse approach to disease control has gained popularity. Instead of trying just to reduce the bacterial challenge through antimicrobial/antibiotic therapy, modulating the host response to decrease the inflammatory destruction of the tissue, could be a more efficient and effective way of controlling the disease In decreasing the inflammatory environment, the pathogenic bacteria feeding off the inflammatory exudate would be greatly decreased, effecting a major change in the microbiome. To date nobody has characterized this change.
The purpose of the study is to test the effects of oral NSAIDS on the peri-implant microbiome. Also, clinical parameters will be tested for correlation with the microbial findings.
Methods:
The study design is random controlled double blind clinical trial. Patients visiting the graduate periodontal clinic at the Hadassah Medical Center will be examined for eligibility for the study. Implants with peri-implant mucositis (clinical signs of inflammation without radiographically bone loss) will be included. Patients (n=50) will undergo clinical examination (which will include probing depths, presence or absence of suppuration and bleeding on probing) and sampling of the subgingival bacterial deposits using a perio-strip. Patients will be randomly assigned to the experimental flurbiprofen group (100 mg bid) or placebo group (n=25 for each group). Drug consumption will be set for the duration of 2 weeks. At the end of drug intake period (day 14) and two weeks afterwards (day 28) all subjects will be re-examined, which will include a new clinical exam and sampling of the subgingival bacterial deposits. The microbiological samples will be analyzed using 16s Ribosomal Pyro-sequencing. The microbiome profile of the Flurbiprofen group before and after treatment and two weeks post-treatment will be compared. as well as the microbiome from the placebo group compared with the Flurbiprofen group. Statistical differences will be evaluated using ANOVA with Bonferroni correction. Correlation between the clinical parameters and microbiological parameters will be tested using Pearson correlation.
Significance:
The study asks the question whether the use of a well-known NSAID that had proven beneficial effects in maintaining the mucosal tissue integrity around implants and help control and prevent peri-implant inflammation. Studies have shown that implants placed 5 years previously will most likely have some form of peri-implant mucositis . Just as gingivitis can lead to periodontal disease, Peri-implant mucositis can lead to peri-implantitis a more destructive inflammatory disease that puts implant survival in jeopardy. Therefore, a drug that can limit the amount of destructive bacteria around the implant can be a very effective non-invasive method of treatment. Additionally with the use of a more comprehensive taxonomical identification of the peri-implant micro-genome, there will be a better understanding of the bacterial role in the destructive process associated with peri-implant inflammation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flurbiprofen
Flurbiprofen 100 mg bid.
Flurbiprofen
100 mg twice a day for 14 days
Placebo
Placebo taken bid
Placebo Oral Tablet
placebo group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flurbiprofen
100 mg twice a day for 14 days
Placebo Oral Tablet
placebo group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* peptic ulcer
* pregnancy
* smoking
* diabetes mellitus
* having taken any antibiotic drug within the previous 6 weeks
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Polak David
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Polak David
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Polak, DMD PhD
Role: PRINCIPAL_INVESTIGATOR
Hadassah Medical Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000. 2000 Oct;24:239-52. doi: 10.1034/j.1600-0757.2000.2240112.x.
Jeffcoat MK, Reddy MS, Wang IC, Meuninghoff LA, Farmer JB, Koth DL. The effect of systemic flurbiprofen on bone supporting dental implants. J Am Dent Assoc. 1995 Mar;126(3):305-11; quiz 346-7. doi: 10.14219/jada.archive.1995.0173.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0674-16-HMO
Identifier Type: -
Identifier Source: org_study_id